News & Noteworthy

CSL Behring Presents Data on Therapeutic Potential of Idelvion: CSL Behring recently reported new results from its phase III clinical development program designed to evaluate Idelvion®. The findings were presented at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3-6, 2016, in San Diego, CA.  Read More

Tretten, Novo Nordisk's Recombinant Therapy for Congenital Factor XIII A-subunit deficiency, Available Through BDI Pharma: Learn More

Cloud-based DSCSA Portal Available for BDI Pharma Customers: Customers now can receive and access all required transaction data from BDI Pharma via electronic portal.  Read More

 

Programs and Subsidiary Companies

  •  

Browse our entire product portfolio and feel free to use the new order inquiry form to receive more information about any of the products that we carry.

Quality Customer Service

BDI Representatives are on-call for your emergency and after-hours needs. Call 1-800-948-9834 for more information or to place an order today.

Contact Us